Dronedarone: Emergence of a new therapeutic option for the treatment of atrial fibrillation

Hospital Pharmacy

Volumn 44, Issue 7, 2009, Pages 562-568

  Howard, Patricia A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DRONEDARONE; PLACEBO;

BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HOSPITALIZATION; HUMAN; LUNG TOXICITY; MORTALITY; PHARMACIST; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SINUS RHYTHM; SKIN DISEASE; THYROID DISEASE; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 70349958203     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4407-562     Document Type: Review

References (18)

1. Conway E, Musco S, Kowey PR. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol. 2008;102(6A): 12H-19H.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469-473.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370-2375.
4. Singer DE, Albers GW, Dalen JE, et al; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133 (6)(suppl):546S-592S.
5. Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation); developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published correction appears in Circulation. 2007;116(6): e138]. Circulation. 2006;114(7):e257-e354.
6. Hohnloser SH, Kuck KH, Lillenthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244): 1789-1794.
7. Wyse DG, Waldo AL, DiMarco JP, et al; The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
8. Van Gelder IC, Hagens VE, Bosker HA, et al; The Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23): 1834-1840.
9. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-1696. (Pubitemid 36584236)
10. Mason JW. Amiodarone. N Engl J Med. 1987;316(8):455-466.
11. Chow MS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother. 1996;30 (6):637-643. (Pubitemid 26184409)
12. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298 (11):1312-1322. (Pubitemid 47449439)
13. Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(11):1220-1226.
14. Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987-999.
15. Køber L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-2687.
16. Hohnloser SH, Crijns HJ, van Eickels M, et al; ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668-678.
17. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone [news release]. Paris, France: sanofi-aventis; December 23, 2008. http://www.info-financiere.fr/upload /FCECO009831-20081223.pdf. Accessed April 8, 2009.
18. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64(6):785-791. (Pubitemid 350222063)